Inflation expectations are on the rise, but what happens if those expectations fail to materialise?
If it continues as many expect, the recent emerging-markets revival could herald a third major period of EM outperformance.
Ahead of its 90th anniversary, Harriman House has re-released Technical Analysis as part of its Definitive edition series with a new foreword from commodity trader Peter L. Brandt. Richard Gill, CFA, reviews.
There is nothing we Brits like as much as talking ourselves down but has the negativity towards the UK’s prospects gone too far?
With dividends being resumed and the vaccination programme well underway, British income stocks could be on the verge of a fast recovery.
Filipe R. Costa explores the merits of investing in clean water through thematic ETFs.
Richard Gill, CFA, reviews three companies he thinks could contribute significantly to both your ISA dividend income and capital growth over the next few years.
A developer of best-in-class targeted therapeutics has had its near- clinic ready TYK2/JAK 1 inhibitor programme earmarked as a potential therapy for severe Covid-19.
Some pharmaceutical companies have managed to develop a coronavirus vaccine in record time, while others have given up.
Richard Gill, CFA, reviews When the Fund Stops, the untold story behind the downfall of Neil Woodford, Britain’s most successful fund manager.